Clinical Trial Update: Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer [Phase 3]

View source ↗

Summary

Phase III trial comparing docetaxel alone versus docetaxel plus ZD1839 (gefitinib) in recurrent or metastatic head and neck cancer was terminated; results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Iressa (gefitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Status: TERMINATED | Results posted: 2015-05-06